Advertisement

Der Pneumologe

, Volume 15, Issue 6, pp 437–448 | Cite as

Lungenbeteiligung bei Herzkrankheiten

  • F. J. Meyer
  • S. Andreas
  • M. Held
  • H. Leuchte
  • H. Worth
CME
  • 255 Downloads

Zusammenfassung

Die Lungenbeteiligung bei Herzkrankheiten ist nicht immer eine direkte Schädigung, sondern oftmals eine Folge komplexer kardiorespiratorischer Interaktionen. Anhand 5 ausgewählter Situationen – Lungenfunktion und Ventilation im Schlaf bei chronischer Linksherzinsuffizienz, alveoläre Hämorrhagie unter Antikoagulation, infektiöse Rechtsherzendokarditis, Auswirkungen herzchirurgischer Eingriffe auf pulmonale Funktionen sowie Belastungsreaktion und Atemmuskelfunktion bei idiopathischer pulmonal arterieller Hypertonie – werden die diagnostischen und therapeutischen Herausforderungen dargestellt.

Schlüsselwörter

Kongestive Herzinsuffizienz Alveoläre Hämorrhagie Endokarditis Herzchirurgie Idiopathische pulmonal arterielle Hypertonie 

Pulmonary involvement in cardiac diseases

Abstract

Pulmonary involvement in patients with cardiac diseases is not always a direct injury but often due to complex cardiopulmonary interactions. In five selected situations, e.g. lung function and nocturnal ventilation in congestive cardiac failure, alveolar hemorrhage complicating anticoagulation, infective right heart endocarditis, effects of cardiac surgery on pulmonary function as well as exercise reaction and respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension, the diagnostic approach and therapeutic management are illustrated.

Keywords

Heart failure, congestive Alveolar hemorrhage Endocarditis Cardiac surgery Idiopathic pulmonary hypertension 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

F.J. Meyer gibt folgenden möglichen Interessenkonflikt an: Vortrag (Boehringer Ingelheim, Novartis). S. Andreas gibt folgende mögliche Interessenkonflikte an: Advisory Board (GSK, Boehringer Ingelheim und Pfizer), Vortrag (Actelion, Almirall, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, GSK, Novartis, Nycomed, Pfizer, Roche), Investigator initiierte Studie (Pfizer, Boehringer Ingelheim). H. Worth gibt folgende mögliche Interessenkonflikte an: Advisory Board (AstraZeneca, BerlinChemie, Chiesi, Circassia, GSK, Klosterfrau, MSD, Novartis), Vortrag (Novartis). M. Held gibt an Honorare für Vorträge von Actelion, Bayer HealthCare, Berlin Chemie, Boehringer Ingelheim, GSK, Novartis, Pfizer erhalten zu haben und Honorare für Beratung von Actelion, Bayer HealthCare, GSK, MSD erhalten zu haben sowie an klinischen Studien folgender Firmen als Prüfarzt mitgewirkt zu haben: Actelion, Bayer HealthCare, GSK, Pfizer, United Therapeutics. H. Leuchte gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agusti A (2016) Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med 194(11):1319–1336CrossRefGoogle Scholar
  2. 2.
    Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP et al (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391(10120):572–580CrossRefGoogle Scholar
  3. 3.
    Chen YGH, Xu D, Xu X, Wang H, Hu X, Lu Z, Kwak D, Xu Y, Gunther R, Huo Y, Weir EK (2012) Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 59:9Google Scholar
  4. 4.
    Hawkins NM, Virani S, Ceconi C (2013) Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 34(36):2795–2803CrossRefGoogle Scholar
  5. 5.
    Andreas S, Morguet AJ, Werner GS, Kreuzer H (1996) Ventilatory response to exercise and to carbon dioxide in patients with heart failure. Eur Heart J 17(5):750–755CrossRefGoogle Scholar
  6. 6.
    Chua TP, Coats AJ (1995) The lungs in chronic heart failure. Eur Heart J 16(7):882–887CrossRefGoogle Scholar
  7. 7.
    Clark AL, Poole-Wilson PA, Coats AJ (1996) Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 28(5):1092–1102CrossRefGoogle Scholar
  8. 8.
    Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P et al (2008) The ventilatory classification system effectively predicts hospitalization in patients with heart failure. J Cardiopulm Rehabil Prev 28(3):195–198CrossRefGoogle Scholar
  9. 9.
    Apostolo ALP, Palange P, Agalbato C, Molle R, Popovic D (2015) Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. Int J Cardiol 189:7CrossRefGoogle Scholar
  10. 10.
    Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kubler W et al (2001) Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 103(17):2153–2158CrossRefGoogle Scholar
  11. 11.
    Filusch A, Ewert R, Altesellmeier M, Zugck C, Hetzer R, Borst MM et al (2011) Respiratory muscle dysfunction in congestive heart failure—the role of pulmonary hypertension. Int J Cardiol 150(2):182–185CrossRefGoogle Scholar
  12. 12.
    Bauer R, Dehnert C, Schoene P, Filusch A, Bartsch P, Borst MM et al (2007) Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Respir Med 101(11):2366–2369CrossRefGoogle Scholar
  13. 13.
    Haarmann H, Folle J, Nguyen XP, Herrmann P, Heusser K, Hasenfuss G et al (2016) Sympathetic activation is associated with exercise limitation in COPD. COPD 13(5):589–594CrossRefGoogle Scholar
  14. 14.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37(27):2129–2200 (Developed with the special contribution of the Heart Failure Association (HFA) of the ESC)CrossRefGoogle Scholar
  15. 15.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC et al (2018) Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med 6(5):368–378CrossRefGoogle Scholar
  16. 16.
    Eulenburg C, Wegscheider K, Woehrle H, Angermann C, d’Ortho MP, Erdmann E et al (2016) Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis. Lancet Respir Med 4(11):873–881CrossRefGoogle Scholar
  17. 17.
    Kip MS, Schönfelder T, Bleß H‑H (2015) Weißbuch Schlaganfallprävention bei Vorhofflimmern. Thieme, StuttgartGoogle Scholar
  18. 18.
    Nitta K, Imamura H, Akihiro Yashio A et al (2016) Diffuse alveolar hemorrhage associated with Edoxaban Therapy. Case Rep Crit Care.  https://doi.org/10.1155/2016/7938062 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chen BC, Sheth NR, Dadzie KA, Smith SW, Nelson LS, Hoffman RS et al (2013) Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis 62(3):591–594CrossRefGoogle Scholar
  20. 20.
    Wijnen PA, Linssen CF, Haenen GR, Bekers O, Drent M (2010) Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 14(1):23–30CrossRefGoogle Scholar
  21. 21.
    Greening AP, Hughes JM (1981) Serial estimations of carbon monoxide diffusing capacity in intrapulmonary haemorrhage. Clin Sci 60(5):507–512CrossRefGoogle Scholar
  22. 22.
    Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr., Tleyjeh IM, Rybak MJ et al (2015) Infective Endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 132(15):1435–1486CrossRefGoogle Scholar
  23. 23.
    Habib G, Lancellotti P, Iung B (2016) 2015 ESC Guidelines on the management of infective endocarditis: a big step forward for an old disease. Heart 102(13):992–994CrossRefGoogle Scholar
  24. 24.
    Frantz S, Buerke M, Horstkotte D et al (2016) Kommentar zu den 2015 Leitlinien der Europäischen Gesellschaft für Kardiologie zur Infektiösen Endokarditis. Kardiologe 10:7.  https://doi.org/10.1007/s12181-016-0058-4 CrossRefGoogle Scholar
  25. 25.
    Szelkowski LA, Puri NK, Singh R, Massimiano PS (2015) Current trends in preoperative, intraoperative, and postoperative care of the adult cardiac surgery patient. Curr Probl Surg 52(1):531–569CrossRefGoogle Scholar
  26. 26.
    Urell C, Westerdahl E, Hedenstrom H, Janson C, Emtner M (2012) Lung function before and two days after open-heart surgery. Crit Care Res Pract 2012:291628PubMedPubMedCentralGoogle Scholar
  27. 27.
    Westerdahl E, Lindmark B, Bryngelsson I, Tenling A (2003) Pulmonary function 4 months after coronary artery bypass graft surgery. Respir Med 97(4):317–322CrossRefGoogle Scholar
  28. 28.
    Urell C, Emtner M, Hedenstrom H, Westerdahl E (2016) Respiratory muscle strength is not decreased in patients undergoing cardiac surgery. J Cardiothorac Surg 11:41CrossRefGoogle Scholar
  29. 29.
    Taggart DP (2000) Respiratory dysfunction after cardiac surgery: effects of avoiding cardiopulmonary bypass and the use of bilateral internal mammary arteries. Eur J Cardiothorac Surg 18(1):31–37CrossRefGoogle Scholar
  30. 30.
    Altarabsheh SE, Deo SV, Dunlay SM, Erwin PJ, Obeidat YM, Navale S et al (2017) Meta-analysis of usefulness of concomitant mitral valve repair or replacement for moderate ischemic mitral regurgitation with coronary artery bypass grafting. Am J Cardiol 119(5):734–741CrossRefGoogle Scholar
  31. 31.
    Weissman C (2004) Pulmonary complications after cardiac surgery. Semin Cardiothorac Vasc Anesth 8(3):185–211CrossRefGoogle Scholar
  32. 32.
    Allou N, Bronchard R, Guglielminotti J, Dilly MP, Provenchere S, Lucet JC et al (2014) Risk factors for postoperative pneumonia after cardiac surgery and development of a preoperative risk score. Crit Care Med 42(5):1150–1156CrossRefGoogle Scholar
  33. 33.
    He S, Chen B, Li W, Yan J, Chen L, Wang X et al (2014) Ventilator-associated pneumonia after cardiac surgery: a meta-analysis and systematic review. J Thorac Cardiovasc Surg 148(6):3148–3155 (e1–5)CrossRefGoogle Scholar
  34. 34.
    Stephens RS, Shah AS, Whitman GJ (2013) Lung injury and acute respiratory distress syndrome after cardiac surgery. Ann Thorac Surg 95(3):1122–1129CrossRefGoogle Scholar
  35. 35.
    Hulzebos EH, Helders PJ, Favie NJ, De Bie RA, Brutel de la Riviere A, Van Meeteren NL (2006) Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA 296(15):1851–1857CrossRefGoogle Scholar
  36. 36.
    Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 46(4):903–975 (The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT))CrossRefGoogle Scholar
  37. 37.
    Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J et al (2002) Peripheral airway obstruction in primary pulmonary hypertension. Thorax 57(6):473–476CrossRefGoogle Scholar
  38. 38.
    Laveneziana P, Humbert M, Godinas L, Joureau B, Malrin R, Straus C et al (2015) Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J 45(5):1495–1498CrossRefGoogle Scholar
  39. 39.
    Naeije R (2014) Lung mechanics and exertional dyspnea in pulmonary arterial hypertension. Respiration 88(1):16–17CrossRefGoogle Scholar
  40. 40.
    Laveneziana P, Garcia G, Joureau B, Nicolas-Jilwan F, Brahimi T, Laviolette L et al (2013) Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J 41(3):578–587CrossRefGoogle Scholar
  41. 41.
    Droste AS, Rohde D, Voelkers M, Filusch A, Bruckner T, Borst MM et al (2009) Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension. Respir Res 10:129CrossRefGoogle Scholar
  42. 42.
    Meyer FJ, Lossnitzer D, Kristen AV, Schoene AM, Kubler W, Katus HA et al (2005) Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension. Eur Respir J 25(1):125–130CrossRefGoogle Scholar
  43. 43.
    Kabitz HJ, Schwoerer A, Bremer HC, Sonntag F, Walterspacher S, Walker D et al (2008) Impairment of respiratory muscle function in pulmonary hypertension. Clin Sci 114(2):165–171CrossRefGoogle Scholar
  44. 44.
    Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2001) Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 104(4):429–435CrossRefGoogle Scholar
  45. 45.
    Dumitrescu D, Sitbon O, Weatherald J, Howard LS (2017) Exertional dyspnoea in pulmonary arterial hypertension. Eur Respir Rev.  https://doi.org/10.1183/16000617.0039-2017 CrossRefPubMedGoogle Scholar
  46. 46.
    Richter MJ, Tiede H, Morty RE, Voswinckel R, Seeger W, Schulz R et al (2014) The prognostic significance of inspiratory capacity in pulmonary arterial hypertension. Respiration 88(1):24–30CrossRefGoogle Scholar
  47. 47.
    Richter MJ, Voswinckel R, Tiede H, Schulz R, Tanislav C, Feustel A et al (2012) Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. Respir Med 106(2):308–313CrossRefGoogle Scholar
  48. 48.
    Meyer FJ, Borst MM, Buschmann HC, Ewert R, Friedmann-Bette B, Ochmann U et al (2013) Exercise testing in respiratory medicine. Pneumologie 67(1):16–34CrossRefGoogle Scholar
  49. 49.
    Yan S, Kaminski D, Sliwinski P (1997) Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156(1):55–59CrossRefGoogle Scholar
  50. 50.
    Criee CP, Baur X, Berdel D, Bosch D, Gappa M, Haidl P et al (2015) Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine. Pneumologie 69(3):147–164CrossRefGoogle Scholar
  51. 51.
    Naeije R (2005) Breathing more with weaker respiratory muscles in pulmonary arterial hypertension. Eur Respir J 25(1):6–8CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • F. J. Meyer
    • 1
  • S. Andreas
    • 2
  • M. Held
    • 3
  • H. Leuchte
    • 4
  • H. Worth
    • 5
  1. 1.Lungenzentrum München (LZM Bogenhausen – Harlaching)Städtisches Klinikum München GmbHMünchenDeutschland
  2. 2.Lungenfachklinik Immenhausen und Bereich Pneumologie (F & L)Universitätsmedizin GöttingenGöttingenDeutschland
  3. 3.Standort MissioklinikKlinikum Würzburg Mitte gGmbHWürzburgDeutschland
  4. 4.2. Medizinische Abteilung – Pneumologie mit Beatmungsmedizin und SchlaflaborKrankenhaus NeuwittelsbachMünchenDeutschland
  5. 5.Facharztforum FürthFürthDeutschland

Personalised recommendations